GamaMabs Pharma
Develops innovative monoclonal antibodies against cancer
Total raised
€18M
€18,100,000
Funding rounds
2
Investors
4
distinct backers
Active since
2013-08
latest 2015-11
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood20
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 13y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-12-01 | Series B | €15M | Alto Invest,Edmond de Rothschild Venture Capital,iXO Private Equity | View deal → |
| 2013-09-01 | Series A | €3.1M | Bpifrance | View deal → |
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software